Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rosiglitazone × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 4 Endocrine 4 Genitourinary 3 Lymphoid 2 Gastrointestinal 2 Dermatologic 2 Tumor-Agnostic 1 Sarcoma 1 Other 1 CNS 1 Breast 1

Conditions

Sarcoma 1 Liposarcoma 1

Interventions

Radiotherapy 202 Cyclophosphamide 198 Doxorubicin 193 Temozolomide 170 Ifosfamide 112 Filgrastim 101 Imatinib Mesylate 95 Etoposide 94 Vincristine 86 Bevacizumab 77 Gemcitabine 76 Irinotecan 75 Magnetic Resonance Spectroscopy 71 pembrolizumab 65 Radiation 64 Carboplatin 59 pazopanib 57 Methotrexate 57 fludarabine phosphate 54 Cisplatin 53 Specimen Handling 51 Nivolumab 51 Trabectedin 49 Surgical Procedures, Operative 49 Peripheral Blood Stem Cell Transplantation 49 Biopsy 47 Docetaxel 44 Busulfan 44 Melphalan 42 fludarabine 39

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00004180 2023-06-26

Rosiglitazone in Treating Patients With Liposarcoma

Dana-Farber Cancer Institute

Phase 2 Completed

Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡